DCAF16 Antibody

What is DCAF16 and why is it significant in research?

DCAF16 (also known as C4orf30) is a 24.2 kilodalton protein that functions as part of the DDB1 and CUL4 associated factor family . It has gained significant attention in recent research due to its role in covalent molecular glue mechanisms and targeted protein degradation pathways. DCAF16 has been identified as a critical component in the mechanism of action for certain degrader compounds like TMX1 and GNE11, which induce cellular toxicity through DCAF16-dependent pathways . Understanding DCAF16 is essential for researchers developing novel approaches to targeted protein degradation and investigating molecular mechanisms of drug action.

What types of DCAF16 antibodies are available for research applications?

Multiple types of DCAF16 antibodies are available for research purposes, including:

• Polyclonal antibodies derived from rabbits, which recognize multiple epitopes of DCAF16

• Antibodies targeting specific regions (such as the N-terminal region)

• Monoclonal antibodies like the F8E1P Rabbit mAb, which provide high specificity

These antibodies vary in their applications, with most validated for Western Blot (WB) analysis, while some are also suitable for immunoprecipitation (IP), ELISA, and various immunohistochemistry techniques (IHC-p, ICC/IF) . The choice between these antibody types depends on your specific experimental requirements and the level of specificity needed.

How does DCAF16 function in the context of the CUL4-DDB1 E3 ligase complex?

DCAF16 functions as a substrate receptor within the CUL4-DDB1 E3 ubiquitin ligase complex. This complex plays a crucial role in protein degradation pathways by mediating the ubiquitination of target proteins, marking them for subsequent degradation by the proteasome. Recent research has revealed DCAF16's capability to participate in covalent molecular interactions, particularly at cysteine residue C119, which can be engaged by certain compounds to approximately 28% in cellular contexts . This property makes DCAF16 particularly valuable in the development of targeted protein degradation technologies, as it can be recruited by certain molecules to bring the E3 ligase complex into proximity with target proteins, facilitating their ubiquitination and subsequent degradation.

What are the validated applications for DCAF16 antibodies in protein detection?

DCAF16 antibodies have been validated for multiple experimental applications, with varying degrees of effectiveness depending on the specific antibody:

For optimal results in Western blot applications, researchers should use appropriate loading controls and optimize antibody dilutions (typically 1:1000-1:2000) based on the specific antibody manufacturer's recommendations. The detection of DCAF16 may require longer exposure times than commonly used proteins due to its relatively lower expression levels in some cell types.

How can I optimize Western blot protocols for DCAF16 detection?

Optimizing Western blot protocols for DCAF16 detection requires attention to several key factors:

• Sample preparation: Complete cell lysis is essential; use RIPA or NP-40 buffer supplemented with protease inhibitors to prevent degradation of DCAF16.

• Protein loading: Load 20-50 μg of total protein per lane, as DCAF16 expression may be moderate to low in some cell lines.

• Separation: Use 10-12% SDS-PAGE gels for optimal resolution around the 24.2 kDa range where DCAF16 is expected .

• Transfer conditions: Semi-dry transfer at 15V for 30-45 minutes or wet transfer at 100V for 1 hour typically provides efficient transfer of DCAF16.

• Blocking: 5% non-fat dry milk in TBST is generally effective, though some antibodies may perform better with BSA-based blocking solutions.

• Primary antibody incubation: Dilute according to manufacturer recommendations (typically 1:500-1:2000) and incubate overnight at 4°C for optimal sensitivity.

• Washing: Perform 4-5 thorough washes with TBST to reduce background signal.

• Detection system: Both chemiluminescent and fluorescent secondary antibodies work well; choose based on your available imaging equipment and desired sensitivity.

For challenging samples, consider enrichment strategies such as immunoprecipitation prior to Western blot analysis to enhance detection sensitivity.

What controls should be included when performing immunohistochemistry with DCAF16 antibodies?

When performing immunohistochemistry with DCAF16 antibodies, include the following controls to ensure reliable and interpretable results:

• Positive control: Include tissue samples known to express DCAF16 (such as specific human cancer cell lines documented to express DCAF16).

• Negative control: Process serial sections of your experimental tissue without primary antibody but with all other reagents to assess background staining.

• Isotype control: Use matched isotype antibody at the same concentration as your DCAF16 antibody to identify potential non-specific binding.

• Blocking peptide control: If available, pre-incubate the DCAF16 antibody with its immunizing peptide to confirm specificity.

• DCAF16 knockout/knockdown samples: If possible, include tissue or cells with DCAF16 gene knockout or knockdown as the gold standard negative control.

Additionally, compare staining patterns across multiple DCAF16 antibodies targeting different epitopes to confirm specificity, particularly when characterizing a new tissue type or experimental condition. This multi-antibody approach helps verify that the observed signals truly represent DCAF16 protein distribution.

Why might I be getting inconsistent results with DCAF16 antibodies in Western blot?

Inconsistent results with DCAF16 antibodies in Western blot experiments can stem from several sources:

• Sample preparation issues: DCAF16 may be sensitive to certain lysis conditions. Ensure complete protease inhibition during sample preparation to prevent degradation. Consider using freshly prepared samples or storing at -80°C with protease inhibitors.

• Antibody specificity: Some DCAF16 antibodies may cross-react with related proteins. Validate your antibody using positive and negative controls, including DCAF16 knockdown or knockout samples if available .

• Detection limitations: If DCAF16 expression is low in your sample, standard detection methods may be insufficient. Consider using high-sensitivity detection systems or signal amplification methods.

• Post-translational modifications: DCAF16 undergoes covalent modifications in certain contexts, which may affect antibody recognition . These modifications might alter the migration pattern or epitope accessibility.

• Batch-to-batch variability: Polyclonal antibodies in particular may show batch variations. If possible, validate each new lot against a previously successful lot.

To address these issues, consider using multiple antibodies targeting different DCAF16 epitopes, implementing more sensitive detection methods, and carefully controlling sample preparation conditions to preserve protein integrity.

How can I validate the specificity of a DCAF16 antibody?

Validating the specificity of a DCAF16 antibody is crucial for experimental reliability. Implement these complementary approaches:

• Genetic validation:

  • Use CRISPR-Cas9 to generate DCAF16 knockout cell lines

  • Employ siRNA or shRNA for transient DCAF16 knockdown

  • Compare antibody signal between wild-type and knockout/knockdown samples in Western blots

• Recombinant protein validation:

  • Test antibody against purified recombinant DCAF16 protein

  • Perform peptide competition assays using the immunizing peptide

• Orthogonal validation:

  • Correlate protein detection with mRNA expression data

  • Compare results across multiple antibodies targeting different DCAF16 epitopes

  • Use mass spectrometry to confirm the identity of the detected band

• Functional validation:

  • Examine if detected protein participates in expected protein-protein interactions

  • Confirm appropriate subcellular localization

  • Verify the protein's response to stimuli known to affect DCAF16 levels

For example, research has demonstrated DCAF16 specificity through CRISPR-Cas9 screens, where sgRNAs targeting DCAF16 conferred resistance to certain degraders in competitive growth assays, confirming DCAF16's functional role .

What factors affect DCAF16 detection sensitivity in immunoprecipitation experiments?

Multiple factors can influence DCAF16 detection sensitivity in immunoprecipitation (IP) experiments:

• Antibody quality and format: Monoclonal antibodies like F8E1P Rabbit mAb have demonstrated superior performance in IP applications compared to some polyclonal options . The antibody's affinity for native (non-denatured) DCAF16 is particularly important for IP success.

• Expression levels: DCAF16 may be expressed at relatively low levels in some cell types, requiring larger input amounts of cellular material.

• Buffer composition: The choice of lysis and washing buffers significantly impacts IP efficiency:

  • Use non-denaturing lysis buffers (e.g., NP-40 or Triton X-100 based) that preserve protein-protein interactions

  • Include appropriate salt concentrations (typically 150-300 mM NaCl) to reduce non-specific binding

  • Add protease inhibitors freshly before each experiment

• Protein-protein interactions: DCAF16 functions within protein complexes, particularly the CUL4-DDB1 E3 ligase complex. These interactions may mask antibody epitopes or affect extraction efficiency.

• Covalent modifications: DCAF16 can undergo covalent modifications at specific residues like C119, which may affect antibody recognition . Consider the experimental context and potential chemical modifiers that might alter DCAF16's immunoreactivity.

• Crosslinking considerations: For challenging interactions, consider using membrane-permeable crosslinking agents before cell lysis to stabilize transient interactions with DCAF16.

To optimize IP experiments, begin with a high-quality antibody validated specifically for IP applications, and systematically optimize buffer conditions to maximize signal while minimizing background.

How does DCAF16 participate in targeted protein degradation mechanisms?

DCAF16 plays a crucial role in engineered targeted protein degradation systems as demonstrated by recent research. DCAF16 functions as a substrate receptor within the CUL4-DDB1 E3 ubiquitin ligase complex and possesses unique properties that enable its recruitment in covalent degrader technologies:

• Covalent engagement mechanism: DCAF16 contains reactive cysteine residues, particularly C119, that can form covalent bonds with electrophilic compounds . This covalent reactivity is critical for certain degrader molecules to recruit DCAF16 to target proteins.

• Template-assisted modification: Research has shown that compounds built on templates like JQ1 can induce DCAF16-dependent covalent molecular glue mechanisms . The addition of electrophiles to specific positions on these templates enables DCAF16 recruitment.

• Proximity-induced degradation: When recruited by bifunctional molecules, DCAF16 brings the ubiquitin ligase machinery into proximity with target proteins, facilitating their ubiquitination and subsequent proteasomal degradation.

• Target diversity: The DCAF16-based degradation mechanism has demonstrated versatility across multiple protein classes. Studies have shown successful degradation of diverse targets including CDK4, androgen receptor, BTK, SMARCA2/4, and BCR-ABL/c-ABL using DCAF16-recruiting chemical handles .

• Linker-less design: Unlike traditional PROTAC approaches that require linker chemistry, DCAF16-based degraders can function through a linker-less, covalent handle design, offering advantages in molecular design and potentially improved pharmacokinetic properties .

Importantly, research indicates that only partial engagement of DCAF16 (approximately 28% engagement of C119) is sufficient to enable effective protein degradation, consistent with the catalytic nature of the ubiquitination process .

What methods can be used to study DCAF16 interactions with other proteins?

Multiple complementary techniques can be employed to investigate DCAF16 interactions with other proteins:

• Affinity purification coupled with mass spectrometry (AP-MS):

  • Immunoprecipitation with DCAF16 antibodies followed by mass spectrometry has successfully identified DCAF16 interactions

  • Both label-free and SILAC-based quantitative approaches can distinguish specific from non-specific interactions

  • BRD4 BD2 bait experiments have confirmed compound-dependent interactions with DCAF16

• Proximity-based approaches:

  • BioID or TurboID fusion proteins can identify proteins in proximity to DCAF16 in living cells

  • APEX2-based proximity labeling offers temporal resolution for dynamic interactions

  • These methods are particularly valuable for identifying transient or weak interactions

• Fluorescence-based interaction assays:

  • Fluorescence resonance energy transfer (FRET) between DCAF16 and potential partners

  • Bimolecular fluorescence complementation (BiFC) for visualizing interactions in cells

  • Fluorescence correlation spectroscopy (FCS) for quantitative interaction measurements

• Biochemical and biophysical techniques:

  • Surface plasmon resonance (SPR) or bio-layer interferometry (BLI) for kinetic parameters

  • Isothermal titration calorimetry (ITC) for thermodynamic characterization

  • Size exclusion chromatography with multi-angle light scattering (SEC-MALS) for complex stoichiometry

• Crosslinking mass spectrometry:

  • Chemical crosslinking coupled with mass spectrometry can capture direct protein-protein interactions

  • Photo-crosslinking approaches offer spatial precision

• Competitive activity-based protein profiling (ABPP):

  • Has successfully demonstrated engagement of DCAF16's C119 residue by covalent compounds

  • Enables quantification of engagement levels in cellular contexts

Integrating multiple methods provides comprehensive characterization of DCAF16 interactions, their dynamics, and functional consequences.

How can covalent modifications of DCAF16 be identified and characterized?

Identifying and characterizing covalent modifications of DCAF16 requires specialized analytical approaches:

• Mass spectrometry-based identification:

  • Intact protein mass spectrometry has successfully identified template-assisted covalent modifications of DCAF16

  • Bottom-up proteomics with database searching for expected modifications

  • Open modification searches for unbiased discovery of novel modifications

  • Targeted MS/MS approaches for specific sites like C119

• Site-directed mutagenesis:

  • Systematic mutation of reactive residues (particularly cysteines) to identify critical sites

  • Creation of modification-resistant DCAF16 variants

  • Functional testing of mutants to assess the impact of specific modifications

• Chemical probes and labeling strategies:

  • Competitive activity-based protein profiling (ABPP) using electrophilic probes

  • Click chemistry approaches for selective enrichment of modified proteins

  • This approach has successfully demonstrated ~28% engagement of DCAF16's C119 residue

• Structural biology techniques:

  • X-ray crystallography or cryo-EM of modified DCAF16 to visualize structural consequences

  • Hydrogen-deuterium exchange mass spectrometry (HDX-MS) to detect conformational changes

  • NMR spectroscopy for dynamic structural information

• Functional correlation studies:

  • Time-course analysis correlating modification with functional outcomes

  • Dose-dependent studies with modifying compounds

  • Correlation of modification levels with degradation efficiency

Research has shown that compounds like TMX1, GNE11, MMH1, and MMH2 can induce template-assisted covalent modifications of DCAF16, which are essential for their mechanism of action in protein degradation . Importantly, non-reactive analogs (MMH1-NR and MMH2-NR) demonstrated negligible DCAF16 recruitment, confirming the necessity of covalent reactivity for these degrader compounds .

What are the key findings from recent CRISPR-Cas9 screens involving DCAF16?

Recent CRISPR-Cas9 screens have provided significant insights into DCAF16 function:

• Essential role in degrader compound activity:

  • CRISPR-Cas9 resistance screens identified DCAF16 as the most crucial gene required for TMX1- and GNE11-induced cellular toxicity

  • sgRNAs targeting DCAF16 were the most enriched in cells resistant to these compounds

  • This finding demonstrated DCAF16's essential role in mediating the effects of these degrader molecules

• Mechanism specificity:

  • While DCAF16 was required for TMX1 and GNE11 activity, it was not necessary for JQ1-induced cellular toxicity

  • This indicates that DCAF16 mediates specific degradation mechanisms rather than being universally required

• Validation through competitive growth assays:

  • The role of DCAF16 was confirmed through competitive growth assays showing that sgRNAs targeting DCAF16 conferred resistance to degrader compounds

  • These functional assays provided orthogonal validation of the screen results

• E3 ligase identification:

  • Among potential targets identified in screens, DCAF16 emerged as the only E3 ligase component of the Cullin family that could be regulated by NEDD8

  • This unique identification positioned DCAF16 as a key mediator in targeted protein degradation systems

These CRISPR-based findings have established DCAF16 as a critical component in certain degrader compound mechanisms and highlighted its potential utility in developing new approaches to targeted protein degradation.

How has DCAF16 been utilized in the development of targeted protein degradation technologies?

DCAF16 has emerged as a valuable component in novel targeted protein degradation technologies:

• Covalent degrader development:

  • Researchers have created a "DCAF16-based covalent degradative chemical handle" that can be attached to protein-targeting ligands

  • This handle facilitates degradation without requiring traditional linker chemistry used in PROTAC approaches

• Multi-target application:

  • The DCAF16-based degradative handle has demonstrated remarkable versatility across protein classes

  • Successful degradation has been achieved for diverse targets including:

    • CDK4 (cell cycle regulator)

    • Androgen receptor (nuclear receptor)

    • BTK (kinase)

    • SMARCA2/4 (chromatin remodelers)

    • BCR-ABL/c-ABL (oncogenic kinases)

• Mechanistic understanding:

  • Template-assisted covalent modification underlies DCAF16 recruitment

  • Specific electrophilic moieties on degrader compounds form covalent bonds with DCAF16's reactive cysteines, particularly C119

  • Non-reactive analogs (MMH1-NR and MMH2-NR) showed negligible DCAF16 recruitment, confirming covalency is required for activity

• Efficiency considerations:

  • Studies have shown that only modest engagement of DCAF16 (approximately 28% of C119) is sufficient to enable target protein degradation

  • This efficiency reflects the catalytic nature of the ubiquitination process

• Compound optimization:

  • Structure-activity relationships have been developed for DCAF16-recruiting moieties

  • Variations in electrophilic groups and their positioning affect DCAF16 engagement efficiency

  • Optimized compounds show improved selectivity and degradation profiles

These advances have positioned DCAF16 as an important component in the targeted protein degradation toolbox, providing unique advantages for developing therapeutically relevant degrader molecules.

What analytical techniques have been most informative in studying DCAF16-based protein degradation mechanisms?

Multiple analytical techniques have provided crucial insights into DCAF16-based protein degradation mechanisms:

• Mass spectrometry approaches:

  • Immunoprecipitation-mass spectrometry (IP-MS) confirmed direct compound-dependent interactions between BRD4 BD2 and DCAF16

  • Intact mass spectrometry identified specific template-assisted covalent modifications of DCAF16

  • Competitive activity-based protein profiling (ABPP) quantified engagement of DCAF16's C119 residue in cells (~28% engagement)

  • Whole-cell proteomics helped characterize the selectivity profile of degrader compounds

• Genetic and cellular techniques:

  • CRISPR-Cas9 resistance screens identified DCAF16 as essential for degrader activity

  • Competitive growth assays validated DCAF16's role using sgRNA-mediated knockdown

  • Western blotting with DCAF16 antibodies monitored protein levels and interactions

• Biochemical methods:

  • In vitro ubiquitination assays demonstrated the functional consequences of DCAF16 recruitment

  • Binding affinity measurements quantified interaction strengths and kinetics

  • Protein degradation assays using various target proteins showed the versatility of the DCAF16-based mechanism

• Chemical biology approaches:

  • Structure-activity relationship studies with compounds like MMH1/MMH2 and their non-reactive analogs established the importance of covalent reactivity

  • Selective chemical probes enabled targeted analysis of specific interactions

  • Bioorthogonal chemistry facilitated tracking of modified proteins in complex systems

• Structural methods:

  • While not explicitly mentioned in the provided search results, structural biology techniques like X-ray crystallography and cryo-electron microscopy likely contributed to understanding DCAF16-degrader-target complexes

The integration of these techniques has been crucial for elucidating the molecular mechanism, specificity, and efficiency of DCAF16-based targeted protein degradation systems.